PHF6 is an inclusion criterion in 2 clinical trials for acute myeloid leukemia, of which 2 are open and 0 are closed. Of the trials that contain PHF6 status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

PHF6 is an inclusion criterion in 1 clinical trial for acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains PHF6 status and acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].

PHF6 is an inclusion criterion in 1 clinical trial for aplastic anemia, of which 1 is open and 0 are closed. Of the trial that contains PHF6 status and aplastic anemia as inclusion criteria, 1 is phase 1 (1 open) [4].

PHF6 is an inclusion criterion in 1 clinical trial for chronic lymphocytic leukemia/small lymphocytic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PHF6 status and chronic lymphocytic leukemia/small lymphocytic lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

PHF6 is an inclusion criterion in 1 clinical trial for chronic myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains PHF6 status and chronic myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].

PHF6 is an inclusion criterion in 1 clinical trial for chronic myelomonocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains PHF6 status and chronic myelomonocytic leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].

PHF6 is an inclusion criterion in 1 clinical trial for hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PHF6 status and hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

PHF6 is an inclusion criterion in 1 clinical trial for lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PHF6 status and lymphoblastic lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

PHF6 is an inclusion criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains PHF6 status and multiple myeloma as inclusion criteria, 1 is phase 1 (1 open) [4].

PHF6 is an inclusion criterion in 1 clinical trial for myelodysplastic syndrome with excess blasts-2, of which 1 is open and 0 are closed. Of the trial that contains PHF6 status and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 1 is phase 2 (1 open) [4].

PHF6 is an inclusion criterion in 1 clinical trial for myelodysplastic syndromes, of which 1 is open and 0 are closed. Of the trial that contains PHF6 status and myelodysplastic syndromes as inclusion criteria, 1 is phase 1 (1 open) [4].

PHF6 is an inclusion criterion in 1 clinical trial for myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PHF6 status and myeloid neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

PHF6 is an inclusion criterion in 1 clinical trial for non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PHF6 status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

PHF6 is an inclusion criterion in 1 clinical trial for therapy-related chronic myelomonocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains PHF6 status and therapy-related chronic myelomonocytic leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].

PHF6 is an inclusion criterion in 1 clinical trial for therapy-related myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains PHF6 status and therapy-related myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) [4].